Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced it has raised $50 million in Series C financing to support the U.S. commercial launch of its Next-Generation Phenotyping (NGP) rapid Antimicrobial Susceptibility Testing (AST) platform.

The Selux platform will become the system of choice for healthcare providers dedicated to providing best-in-class septic and other infectious diseases patient care." In September 2021, the company received Breakthrough Device Designation from the FDA for positive blood culture and sterile body fluid sample indications for NGP. In October 2021, the company received a $2.8 million award from the U.S. National Institutes of Health (NIH) to help commercialization efforts.

Selux Diagnostics Announces Additional $50 Million In Series C Funding

Description

Company Information

Funding Insights

Selux Diagnostics Announces Additional $50 Million In Series C Funding

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information